Day One Biopharmaceuticals (NASDAQ: DAWN) filing shows 0% Atlas ownership
Rhea-AI Filing Summary
Day One Biopharmaceuticals, Inc. Schedule 13G/A amendment shows a group of Atlas Venture entities collectively reporting zero beneficial ownership in the company’s common stock (CUSIP 23954D109). The filing lists multiple Atlas Venture partnerships and LLCs and is signed by Ommer Chohan on behalf of those entities.
Positive
- None.
Negative
- None.
Key Figures
Document date: 03/31/2026
Signature date: 05/14/2026
Beneficial ownership: 0 shares
+2 more
5 metrics
Document date
03/31/2026
Cover date shown on the amendment
Signature date
05/14/2026
Date signatures by Ommer Chohan were executed
Beneficial ownership
0 shares
Amount beneficially owned reported in Item 4(a)
Percent of class
0%
Percent of class reported in Item 4(b)
CUSIP
23954D109
Identifier for Day One Biopharmaceuticals common stock
Key Terms
Schedule 13G/A, Beneficial ownership, Joint Filing Agreement
3 terms
Schedule 13G/A regulatory
"Amendment No. 4 ) Day One Biopharmaceuticals, Inc."
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficial ownership financial
"Item 4. | Ownership (a) | Amount beneficially owned: 0"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Joint Filing Agreement regulatory
"Exhibit Information JOINT FILING AGREEMENT"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did the Schedule 13G/A filed for DAWN report?
The filing reports that Atlas Venture entities beneficially own 0 shares of Day One Biopharmaceuticals common stock, representing 0% of the class. It identifies multiple Atlas Venture partnerships and LLCs and provides a joint filing agreement signed by Ommer Chohan.
Which Atlas Venture entities are named in the DAWN filing?
Named reporting persons include Atlas Venture Fund XI, L.P., Atlas Venture Associates XI entities, Atlas Venture Opportunity Fund I and II entities, and affiliated LLCs. Each entity’s place of organization is listed as Delaware and the business address is in Cambridge, Massachusetts.
When were the signatures and document date recorded in the filing for DAWN?
The amendment shows a document date of 03/31/2026 on the cover and signature dates of 05/14/2026. Signatures are executed by Ommer Chohan on behalf of the various Atlas Venture reporting entities.
Does the Schedule 13G/A indicate any voting or dispositive power for Atlas Venture in DAWN?
No. The ownership table shows 0 for sole and shared voting power and sole and shared dispositive power, and lists beneficial ownership as 0 shares, representing 0% of the common stock class.